VRXAVoyager Acquisition Corp

$8.34
$1.12
(11.81%)
Pre-Market
Updated: 04:06 AM EDT·Prev Close $9.46
Mkt Cap$672.35M
Vol963.00
News
all
press releases
News Placeholder
Why VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’
VERAXA Biotech (NASDAQ: VRXA) is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications. “The company is focused on the discovery and development of a new generation of antibody-based therapeutics for the treatment of solid tumors. VERAXA’s vision is to deliver the next wave […]
Investor Brand Network
News Placeholder
VERAXA Biotech (NASDAQ: VRXA) Is ‘One to Watch’
VERAXA Biotech has successfully concluded a business combination with Voyager Acquisition Corp. (NASDAQ: VACH) and began trading on the NASDAQ Capital Market under the ticker symbol ‘VRXA’ on June 11, 2026. VERAXA Biotech (NASDAQ: VRXA) is a biotechnology company focused on the discovery and development of a new generation of antibody-based therapeutics for the treatment of solid […]
Investor Brand Network
News Placeholder
VERAXA Biotech (NASDAQ: VRXA) Completes Business Combination, Begins Trading on Nasdaq
VERAXA Biotech (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp. (NASDAQ: VACH), resulting in the formation of VERAXA Biotech AG, which will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. The company is developing a pipeline of bispecific T-cell engagers […]
Investor Brand Network
<
...
1
>

Advertisement|Remove ads.